Histologically confirmed locally advanced gastric (primary endpoint includes proximal and mid-body stomach) or esophagogastric adenocarcinoma; distal gastric (antral) adenocarcinomas are eligible for enrollment but will not be included in the primary analysis
History of gastric or small bowel surgery involving any extent of gastric or small bowel resection.
Squamous cell or undifferentiated gastric cancer
Gastric carcinoma.
Gastric bypass
Symptomatic evidence of gastric outlet obstruction
Uncontrolled or active gastric or duodenal ulcer disease within days of enrollment
Active inflammatory gastrointestinal disease or previous gastric resection or lap band
Advanced Gastric Cancer
History of gastrointestinal mal-absorption or gastric bypass surgery
Have a history of gastric bypass surgery or severe malabsorption that may interfere with the absorption of the study agents
Metastatic or relapsed Gastric cancer (adenocarcinoma) (module )
Presence of duodenal or gastric invasion by the tumor as noted by esophagogastroduodenoscopy (EGD) at time of fiducial placement
Evidence of gross duodenal invasion, gastric outlet obstruction
History of gastric or duodenal ulcers or untreated hyperacidity syndromes
Symptomatic evidence of gastric outlet obstruction
Subject has gastric outlet syndrome or persistent/recurrent vomiting.
Subject with recent gastric bleeding or symptomatic subjects with proven gastric ulcers that would exclude the subject from participation.
Must have operable gastric adenocarcinoma, T-Ta, N-N, M
History of gastric or small bowel surgery.
History of gastric or small bowel surgery involving any extent of gastric or small bowel resection.
Her- positive gastric tumor
No uncontrolled gastric ulcer disease (grade gastric ulcer disease) within days of registration
Subjects (NSCLC and gastric adenocarcinoma) must be determined to have HA-high levels from their tumor biopsies.
Gastric adenocarcinoma subjects with brain metastases
Squamous cell or undifferentiated gastric cancer
Phase expansion: Gastric Cancer
Gastric Cancer
Diagnosis of squamous or undifferentiated gastric cancer
Malabsorption, total gastric resection
Participant has active, high risk bleeding (such as, via gastric ulcers or gastric varices) within days prior to randomization
The participant has squamous cell or undifferentiated gastric cancer.
Squamous cell or undifferentiated gastric cancer
Active uncontrolled gastric or duodenal ulcer
Gastric or duodenal ulcer (at least mm in size) within mm of expected endoscopy puncture site(s) for photodynamic therapy (PDT)
Gastric cancer (including gastric and EGJ cancers): at least prior systemic regimens in adjuvant, advanced, or metastatic setting and, as appropriate, a human epidermal growth factor receptor (HER) targeted agent.
More than one prior line of therapy for advanced gastric cancer
For subjects with gastric cancer:
Prior gastric surgery, small bowel resection, or other conditions that may impede adequate absorption of oral study drug
Patients with clinical bleeding, active gastric, or duodenal ulcer
Impaired gastrointestinal (GI) function such as from significant small bowel resection or gastric bypass surgery or inability to swallow up to five ceritinib capsules daily
Patients who have a history of previous gastric or duodenal surgery
A history of gastric or duodenal ulcers or hyperacidity syndromes
Delayed gastric emptying syndrome
Patients must not have documented history of gastric/duodenal ulcer within the last months; participant must not currently be on treatment for gastric/duodenal ulcer or be experiencing symptoms at study entry; patients with gastroesophageal reflux disease (GERD) are eligible, however, and these patients may receive over-the-counter histamine- (H) antagonists; proton-pump inhibitors, or other prescription-based treatment for GERD
History of gastric ulcer within the past years (with or without bleeding)
Individuals with prior gastric bypass surgery or procedure that would impair absorption of nutrients
History of gastric surgery
Patients with a history of gastric bypass surgery
Individual with history of gastric bypass due to any reason
Gastric paresis
History of gastric ulcer within the past years (with or without bleeding)
Active inflammatory gastrointestinal disease or previous gastric resection or lap band
History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect gastric absorption
Gastric bypass
History of gastric bypass surgery, gastric banding, bowel resection, malabsorption syndromes such as celiac sprue or pancreatic insufficiency, or other conditions that may affect the absorption of kava